SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Sponsor
Fudan University
Study ID
NCT06210438
Phase
PHASE2
Status
Unknown

Conditions

  • Brain Metastasis
  • TNBC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases

Key Dates

First listed
Jan 18, 2024
Start date
Feb 1, 2024
Status verified
Dec 2023
Primary completion
Jun 30, 2025
Completion
Jun 30, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-A1921 + Bevacizumab

Primary Outcome Measure

CNS ORR [ Time Frame: from enrollment to progression or death (for any reason), assessed up to 24 months ]

Central Contacts

Related Studies